Analysis of Second Primary Cutaneous Squamous Cell Carcinoma Tumors Reported During the C-POST Trial - report from ESMO 2025

from Medical Digest & Congress Report · host Medical Congress News

Professor Danny Rischin shares his thoughts on the analysis of second primary cutaneous squamous cell carcinoma tumors reported during the C-POST trial were presented at the ESMO Congress 2025. The study is a randomized phase III study of adjuvant cemiplimab vs placebo for high-risk CSCC.Video: https://medicaldigest.org/scientific-contents/interview:analysis-second-primary-cutaneous-squamous-cell-carcinoma-tumors-reported-during-c-post-trial

Episode metadata supplied by the publisher feed · Published Nov 13, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Analysis of Second Primary Cutaneous Squamous Cell Carcinoma Tumors Reported During the C-POST Trial - report from ESMO 2025

0:00 6:13

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 6 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on November 13, 2025.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!